• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease.

作者信息

Faridi Kamil F, Desai Nihar R

机构信息

Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven CT, United States.

出版信息

Am J Prev Cardiol. 2023 Mar 15;14:100491. doi: 10.1016/j.ajpc.2023.100491. eCollection 2023 Jun.

DOI:10.1016/j.ajpc.2023.100491
PMID:36969953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10036885/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad7/10036885/9a54cb464bae/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad7/10036885/9a54cb464bae/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad7/10036885/9a54cb464bae/gr1.jpg

相似文献

1
Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease.为所有动脉粥样硬化性心血管疾病患者采用联合降脂治疗。
Am J Prev Cardiol. 2023 Mar 15;14:100491. doi: 10.1016/j.ajpc.2023.100491. eCollection 2023 Jun.
2
Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.不断演变的低密度脂蛋白胆固醇管理策略：一种预防动脉粥样硬化性心血管疾病的个体化方法，贯穿整个风险连续谱。
J Am Heart Assoc. 2023 Jun 6;12(11):e028892. doi: 10.1161/JAHA.122.028892. Epub 2023 Jun 1.
3
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].[接受降脂治疗的血脂异常患者动脉粥样硬化性心血管疾病一级和二级预防中胆固醇目标达成情况：中国血脂异常防治研究（DYSIS-China）亚组分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Aug 24;44(8):665-70. doi: 10.3760/cma.j.issn.0253-3758.2016.08.006.
4
LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals.降脂治疗降低 LDL-C 以预防老年人主要血管事件
J Am Coll Cardiol. 2023 Oct 3;82(14):1381-1391. doi: 10.1016/j.jacc.2023.07.027.
5
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估：临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
6
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.降低“极高”ASCVD 风险患者的靶向致动脉粥样硬化脂蛋白胆固醇目标。
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.
7
Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.前瞻性试验的原理与设计：普罗布考对既往冠心病患者动脉粥样硬化事件二级预防的试验
J Atheroscler Thromb. 2016 Jun 1;23(6):746-56. doi: 10.5551/jat.32813. Epub 2016 Jan 22.
8
A Clinical Guide to Combination Lipid-Lowering Therapy.《联合降脂治疗临床指南》
Curr Atheroscler Rep. 2018 Mar 7;20(4):19. doi: 10.1007/s11883-018-0721-2.
9
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.高胆固醇血症的管理、高心血管风险患者治疗方法的适宜性及新药
High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.
10
An update on emerging drugs for the treatment of hypercholesterolemia.治疗高胆固醇血症的新型药物最新进展。
Expert Opin Emerg Drugs. 2021 Dec;26(4):363-369. doi: 10.1080/14728214.2021.2009801. Epub 2021 Dec 6.

引用本文的文献

1
Quantifying the 'distance to LDC-goal' in patients at very high cardiovascular risk with hyperlipidaemia in Germany: a retrospective claims database analysis.量化德国伴有血脂异常的极高心血管风险患者的“与最不发达国家目标的差距”：一项回顾性索赔数据库分析。
Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241277402. doi: 10.1177/17539447241277402.
2
Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models.缩小血脂异常治疗差距：借助数字健康和创新护理模式变革管理方式
Rev Cardiovasc Med. 2023 Dec 13;24(12):350. doi: 10.31083/j.rcm2412350. eCollection 2023 Dec.

本文引用的文献

1
Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies.依折麦布在降脂治疗中的安全性：随机对照试验和队列研究的系统评价与荟萃分析
BMJ Med. 2022 May 3;1(1):e000134. doi: 10.1136/bmjmed-2022-000134. eCollection 2022.
2
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用的专家共识决策路径报告。
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.
3
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.瑞西伐他汀与依折麦布联合中等强度他汀治疗与高强度他汀单药治疗动脉粥样硬化性心血管疾病患者的长期疗效和安全性（RACING）：一项随机、开放标签、非劣效性试验。
Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18.
4
Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.高危患者的低密度脂蛋白胆固醇治疗率：尽管有越来越完善的循证指南，但仍令人失望。
Am J Prev Cardiol. 2021 Apr 23;6:100186. doi: 10.1016/j.ajpc.2021.100186. eCollection 2021 Jun.
5
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.在美国动脉粥样硬化性心血管疾病患者登记库GOULD中，降脂疗法两年以上的使用情况。
JAMA Cardiol. 2021 Sep 1;6(9):1060-1068. doi: 10.1001/jamacardio.2021.1810.
6
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.降脂联合治疗高风险和极高风险患者的实用指南：欧洲动脉粥样硬化学会工作组的声明。
Atherosclerosis. 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039. Epub 2021 Apr 13.
7
Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.依洛尤单抗在心肌梗死围手术期及早期对致动脉粥样硬化脂蛋白的影响：一项安慰剂对照的随机试验。
Circulation. 2020 Jul 28;142(4):419-421. doi: 10.1161/CIRCULATIONAHA.120.046320. Epub 2020 Jul 27.
8
Reasons for Nonadherence to Statins - A Systematic Review of Reviews.不坚持服用他汀类药物的原因——综述的系统评价
Patient Prefer Adherence. 2020 Apr 2;14:675-691. doi: 10.2147/PPA.S245365. eCollection 2020.
9
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.缺血性脑卒中后两种 LDL 胆固醇目标的比较。
N Engl J Med. 2020 Jan 2;382(1):9. doi: 10.1056/NEJMoa1910355. Epub 2019 Nov 18.
10
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.